Physician profile
Manish Shah
NPI 1902826035
$100,784.82
in general payments reported to CMS, 2019-2025
37 companies · $25K in 2025
The $25K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,418 · 2020: $1,850 · 2021: $1,458 · 2022: $28K · 2023: $14K · 2024: $30K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $58K · Food and Beverage: $6,101 · Travel and Lodging: $4,068 · Education: $7.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,380.25 |
| Food and Beverage | $6,100.69 |
| Travel and Lodging | $4,068.05 |
| Education | $7.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $50,627.18 | 2019-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $40,302.72 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $4,153.94 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,386.10 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $804.58 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $455.82 | 2021-2025 | Vraylar, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $356.84 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $340.57 | 2019-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Glaxosmithkline, LLC. | $289.96 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Pfizer INC. | $245.55 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $221.87 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $174.67 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.20 | 2019-2021 | |
| Astellas Pharma US INC | $124.03 | 2023 | |
| Allergan, INC. | $123.31 | 2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $114.65 | 2025 | Overstitch Endoscopic Suturing System |
| Nestle Healthcare Nutrition INC. | $107.34 | 2021-2022 | |
| Merz North America, INC. | $78.34 | 2023 | Xeomin |
| Takeda Pharmaceuticals U.S.A., INC. | $75.74 | 2021-2022 | |
| Abbott Laboratories | $73.98 | 2023-2024 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $66.39 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $56.79 | 2019-2020 | |
| Cranial Technologies, INC | $55.54 | 2020-2023 | Doc Band |
| Myriad Women'S Health, INC. | $54.82 | 2023 | Myrisk |
| Currax Pharmaceuticals LLC | $46.26 | 2020-2025 | Contrave |
| Dexcom, INC. | $45.82 | 2021-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $31.50 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $24.72 | 2020 | |
| Verrica Pharmaceuticals INC. | $24.01 | 2024 | Ycanth |
| Vertical Pharmaceuticals, LLC | $23.97 | 2020 | |
| Phathom Pharmaceuticals, INC. | $22.52 | 2025 | Voquezna |
| Renalytix Ai, INC. | $20.46 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Phadia US INC. | $19.35 | 2024 | Immunocap |
| Idorsia Pharmaceuticals US INC | $16.02 | 2023 | Quviviq |
| Sanofi Pasteur INC. | $15.85 | 2024 | |
| Sumitomo Pharma America, INC. | $15.42 | 2025 | Gemtesa |
| Ultragenyx Pharmaceutical INC. | $13.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.